Pfizer (NYSE:PFE) Upgraded at Wall Street Zen

04 Aug 2026, 06:01 by Tristan Rich · The Markets Daily

Wall Street Zen upgraded shares of Pfizer (NYSE:PFE – Free Report) from a hold rating to a buy rating in a research report report published on Saturday morning.

A number of other research firms also recently issued reports on PFE. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Citigroup raised their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average price target of $28.50.

Get Our Latest Stock Report on PFE

Pfizer Stock Up 0.2%

PFE opened at $25.05 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average price of $25.03 and a 200-day moving average price of $26.16. Pfizer has a twelve month low of $23.40 and a twelve month high of $28.75. The stock has a market capitalization of $142.77 billion, a price-to-earnings ratio of 19.12 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $0.92 earnings per share. Equities research analysts forecast that Pfizer will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in the company. Vermillion Wealth Management Inc. boosted its stake in Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 382 shares during the period. Triad Wealth Partners LLC lifted its position in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC grew its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 390 shares in the last quarter. ETF Store Inc. boosted its holdings in shares of Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares in the last quarter. Finally, Delta Financial Advisors LLC grew its position in Pfizer by 1.6% during the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s roughly 6.9% dividend yield is more than six times the S&P 500 average, making the shares attractive to income-oriented investors despite their weak five-year performance. Pfizer’s Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?
Positive Sentiment: Pfizer is among five major pharmaceutical companies expected to report second-quarter results this week, and a strong start to the broader pharma earnings season has raised hopes that the company could beat forecasts. Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
Positive Sentiment: Analyst price targets tracked over the past six months have a median of $27.50, above Pfizer’s recent trading level, suggesting some potential upside if earnings and management’s outlook reassure investors. Pfizer Stock Opinions on Pipeline Developments and Market Valuation
Neutral Sentiment: Wall Street expects lower second-quarter earnings when Pfizer reports, placing greater importance on revenue trends, cost controls, pipeline progress and full-year guidance. Pfizer Reports Q2 2026 Earnings Tomorrow
Neutral Sentiment: The broader market opened with a favorable tone as falling oil prices supported equities, though this is a general market tailwind rather than a Pfizer-specific catalyst. Falling Oil Boosts Wall Street Pre-Bell
Negative Sentiment: Pre-earnings coverage highlights pressure from legacy products and the need for newer growth bets to offset declining COVID-related sales, reinforcing concerns about Pfizer’s medium-term growth profile. Pfizer, Merck Q2 Preview
Negative Sentiment: Social-media discussion continues to raise questions about vaccine safety perceptions, Pfizer’s pipeline execution and limited buyer interest; these concerns may weigh on sentiment ahead of the earnings release, although they are not verified company announcements. Pfizer Stock Opinions on Pipeline Developments and Market Valuation

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.